Vascular Biogenics Ltd (NASDAQ:VBLT) is moving higher slightly in pre-market trading on Thursday.
As of 7:54, VBLT stock is trading up by 0.50% to $2.23 in the pre-market session with 800 shares have traded hands.
VBLT Announces News
VBL Therapeutics to Provide an Update on the OVAL Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
- VBLT announced that a poster providing an update on the OVAL Phase 3 registration enabling clinical trial of VB-111 in ovarian cancer will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting.
- Title: Clinical Trial in Progress: Pivotal Study of VB-111 Combined with Paclitaxel vs. Paclitaxel for Treatment of Platinum-Resistant Ovarian Cancer (OVAL, VB-111-701/GOG-3018)
“We are encouraged by the continued progress of the OVAL clinical trial, which remains on track,” said Dror Harats, M.D., CEO of VBL Therapeutics. “The poster will provide an important update on the trial.”
|SHARES OUTSTANDING||60.28 M|
|SHARE FLOAT (%)||44.13 M (73.20%)|
|% HELD BY INSTITUTIONS||8.16|
Recent Stock Performance
|+/- EMA(20)||2.03 (+9.36%)|
|+/- SMA(50)||1.98 (+12.12%)|
|+/- SMA(200)||1.71 (+29.82%)|
|CCI20||141.5349||Buy||Chaikin Money Flow||0.1315||Buy|
|MACD||0.0301||Buy||Money Flow Index||67.8311||Buy|
|STOCH (14,3)||77.1930||Buy||STOCH RSI||1.0000||OverBought|